UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Chong Kun Dang to co-promote CJ Healthcare’s gastroesophageal reflux treatment
  • By Lee Han-soo
  • Published 2019.01.22 16:03
  • Updated 2019.01.22 16:03
  • comments 0

CJ Healthcare said Tuesday that it has signed an agreement with Chong Kun Dang to co-promote K-CAB, a gastroesophageal reflux disease (GORD) treatment, in Korea.

CJ Healthcare CEO Kang Seok-hee (right) and Chong Kun Dang CEO Kim Young-joo shake hands after signing the agreement at the Plaza Seoul on Tuesday.

K-CAB is Korea’s 30th novel drug that won the license in July 2018. It became the first potassium-competitive acid blocker (P-CAB) to obtain the indication for erosive and non-erosive GORD. Under the accord, both companies will market and sell the drug in the local market.

While conventional treatments such as proton pump inhibitors (PPI) need three to five days to show efficacy, P-CAB drugs suppress gastric acid secretion within one hour after taking the medication. P-CAB treatments also suppress excessive secretion of gastric acid during night time, which could reduce chest pain and a sleep disorder, according to CJ HealthCare.

“K-CAB tablets, which are characterized by rapid drug efficacy and blocking gastric acid secretion at night, will quickly change the prescription trend of GORD,” CJ Healthcare CEO Kang Seok-hee said. “We are delighted to cooperate with Chong Kun Dang in the local co-promotion activities of our new K-CAB brand, and we expect to demonstrate synergies between the two companies and accelerate the success of K-CAB.”

Chong Kun Dang CEO Kim Young-joo said, “Chong Kun Dang has been steadily increasing its market share through various products in GORD disease market. We will lead the market for GORD in Korea with K-CAB’s superior product quality and the sales and marketing capabilities of Chong Kun Dang and CJ Healthcare.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top